MA49463A - Vaccin contre le virus de l'herpès simplex - Google Patents
Vaccin contre le virus de l'herpès simplexInfo
- Publication number
- MA49463A MA49463A MA049463A MA49463A MA49463A MA 49463 A MA49463 A MA 49463A MA 049463 A MA049463 A MA 049463A MA 49463 A MA49463 A MA 49463A MA 49463 A MA49463 A MA 49463A
- Authority
- MA
- Morocco
- Prior art keywords
- herpes simplex
- simplex vaccine
- vaccine
- herpes
- simplex
- Prior art date
Links
- 229940124725 herpes simplex vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490067P | 2017-04-26 | 2017-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49463A true MA49463A (fr) | 2021-05-05 |
Family
ID=63919141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049463A MA49463A (fr) | 2017-04-26 | 2018-04-25 | Vaccin contre le virus de l'herpès simplex |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200054737A1 (fr) |
| EP (1) | EP3641810A4 (fr) |
| MA (1) | MA49463A (fr) |
| WO (1) | WO2018200737A1 (fr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017020026A1 (fr) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Arn épitopes peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017070601A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv) |
| EP3364981A4 (fr) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| CA3007955A1 (fr) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Nanoparticules de lipide pour l'administration d'agents therapeutiques |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
| EP3555289A1 (fr) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Purification par affinité d'arn |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (fr) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| WO2018232357A1 (fr) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Formulations d'arn |
| AU2018316811B2 (en) | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| WO2019036683A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
| WO2019046809A1 (fr) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| WO2019148101A1 (fr) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Vaccins à base d'arn contre le vrs |
| CN109337868B (zh) * | 2018-06-28 | 2022-04-19 | 武汉滨会生物科技股份有限公司 | 利用vak技术在体外激活免疫细胞的方法 |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061457A1 (fr) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Préparation de nanoparticules lipidiques et leurs méthodes d'administration |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (fr) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Vaccins à base d'arn contre le vih |
| WO2021015987A1 (fr) * | 2019-07-19 | 2021-01-28 | Merck Sharp & Dohme Corp. | Polypeptides de glycoprotéines e antigéniques, compositions et leurs procédés d'utilisation |
| CN113521269A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
| WO2022002783A1 (fr) * | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4225360A1 (fr) * | 2020-10-08 | 2023-08-16 | Virothera Limited | Compositions de vaccins |
| WO2022150717A1 (fr) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Vaccins contre le virus de la grippe à arn saisonnière |
| EP4032546A1 (fr) * | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Vaccin viral thérapeutique |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| AR127311A1 (es) * | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA DELTA DEL SARS-CoV-2 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4444345A2 (fr) * | 2021-12-08 | 2024-10-16 | ModernaTX, Inc. | Vaccins à arnm contre le virus de l'herpès simplex |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
| IL326358A (en) * | 2023-08-03 | 2026-04-01 | Univ Pennsylvania | RNA compositions encoding herpes simplex virus glycoprotein E and/or glycoprotein I antigens and their uses |
| WO2025030165A1 (fr) * | 2023-08-03 | 2025-02-06 | BioNTech SE | Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et procédés associés |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| EP0948508A4 (fr) * | 1996-11-04 | 2001-11-07 | Smithkline Beecham Corp | Nouvelles sequences codantes pour le virus herpes simplex de type 2 |
| CA2370628A1 (fr) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Procedes et compositions pour l'inhibition de la fonction de sequences polynucleotidiques |
| CA2658484A1 (fr) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions et methodes de vaccination contre le hsv-2 |
| US20130028925A1 (en) * | 2006-12-28 | 2013-01-31 | Harvey Friedman | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| EP3520813B1 (fr) * | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Plateformes de délivrance d'antigènes |
| EA033467B1 (ru) * | 2011-01-31 | 2019-10-31 | Univ Pennsylvania | Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение |
| AU2012243039B2 (en) * | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US20140271829A1 (en) * | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
| PT2850431T (pt) * | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
| DK3134131T3 (en) * | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| US20170298389A1 (en) * | 2014-10-10 | 2017-10-19 | Vaxart, Inc. | Hsv vaccines |
| RS63030B1 (sr) * | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| EP3365009A4 (fr) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Vaccin contre le virus de l'herpès simplex |
| AU2016342376A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| EP3532097A1 (fr) * | 2016-10-27 | 2019-09-04 | The Trustees Of The University Of Pennsylvania | Arn à nucléoside modifié destiné à induire une réponse immunitaire adaptative |
| US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| AU2018316811B2 (en) * | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
-
2018
- 2018-04-25 WO PCT/US2018/029456 patent/WO2018200737A1/fr not_active Ceased
- 2018-04-25 MA MA049463A patent/MA49463A/fr unknown
- 2018-04-25 US US16/608,451 patent/US20200054737A1/en not_active Abandoned
- 2018-04-25 EP EP18790572.4A patent/EP3641810A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3641810A4 (fr) | 2021-08-18 |
| US20200054737A1 (en) | 2020-02-20 |
| WO2018200737A1 (fr) | 2018-11-01 |
| EP3641810A1 (fr) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46024A (fr) | Vaccin contre le virus de l'herpès simplex | |
| EP3641810A4 (fr) | Vaccin contre le virus de l'herpès simplex | |
| EP4028030A4 (fr) | Vaccin contre le cytomégalovirus humain | |
| MA50813A (fr) | Vaccins contre le virus d'epstein-barr | |
| EP3364981A4 (fr) | Vaccin contre le cytomégalovirus humain | |
| MA46584A (fr) | Vaccin contre le cytomégalovirus humain | |
| EP3595713A4 (fr) | Vaccin contre le virus respiratoire syncytial | |
| GB2592769B (en) | CpG-Adjuvanted SARS-CoV-2 virus vaccine | |
| EP3668541A4 (fr) | Formulations de vaccin pneumococcique conjugué | |
| MA43762A (fr) | Vaccin contre le rsv | |
| EP3585803A4 (fr) | Formulations de vaccin pneumococcique conjugué | |
| MA46317A (fr) | Vaccin contre le virus respiratoire syncytial | |
| EP3309251A4 (fr) | Vecteur viral de parainfluenza de type 2 humain et vaccin | |
| BR112017013009A2 (pt) | formulação de vírus herpes simplex congelada estável | |
| GB201713163D0 (en) | HPV vaccine | |
| DK3355933T3 (da) | Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser | |
| EP3515929A4 (fr) | Vaccins thérapeutiques contre le virus de l'hépatite b | |
| EP3781195A4 (fr) | Antigènes vaccinaux chimériques contre l'anaplasmose | |
| EP3866847A4 (fr) | Vaccin antiviral | |
| EP3939607A4 (fr) | Vaccin contre le virus de la dengue | |
| EP3891170A4 (fr) | Immunogènes de vaccin contre le vih | |
| DK2941269T3 (da) | Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner | |
| EP3139745B8 (fr) | Vaccins contre les infections de l'herpès simplex génital | |
| GB201811382D0 (en) | Vaccine | |
| GB201702193D0 (en) | Hepatitis E virus vaccine |